NASDAQ: ABCMAbcam PLC Stock
$22.55-0.04 (-0.18%)
Updated Sep 22, 2023
ABCM Price
$22.55
Fair Value Price
N/A
Market Cap
$5.17B
52 Week Low
$12.48
52 Week High
$25.32
P/E
-169.55x
P/B
5.68x
P/S
11.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$480.63M
Earnings
-$30.25M
Gross Margin
75.2%
Operating Margin
-6.27%
Profit Margin
-6.3%
Debt to Equity
0.43
Operating Cash Flow
$51M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABCM Overview
Abcam PLC produces and sells protein research tools for the analysis of living cells at a molecular level. Abcam also develops and markets antibodies and other related products. The company's products are used by researchers to identify proteins for life sciences and veterinary sciences applications. The company distributes its products in the U.S. and internationally. Abcam was incorporated in 1998 and is headquartered in Cambridge, UK.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABCM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABCM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABCM is poor value based on its book value relative to its share price (5.68x), compared to the US Biotechnology industry average (5.11x)
P/B vs Industry Valuation
ABCM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ABCM due diligence checks available for Premium users.
Be the first to know about important ABCM news, forecast changes, insider trades & much more!
ABCM News
Valuation
ABCM fair value
Fair Value of ABCM stock based on Discounted Cash Flow (DCF)
Price
$22.55
Fair Value
$22.84
Undervalued by
1.27%
ABCM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABCM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-169.55x
Industry
12.89x
Market
14.52x
ABCM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.68x
Industry
5.11x
ABCM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABCM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ABCM's Earnings (EBIT) of -$30.13M... subscribe to Premium to read more.
Interest Coverage Financials
ABCM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$389.7M
Debt to equity
0.43
ABCM's short-term assets ($323.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABCM's short-term assets ($323.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABCM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ABCM's operating cash flow ($50.76M)... subscribe to Premium to read more.
Debt Coverage Financials
ABCM vs Biotech Stocks
Abcam Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.